Examples of 'idelalisib' in a sentence
Meaning of "idelalisib"
idelalisib (noun): A medication used in the treatment of certain types of blood cancers, particularly chronic lymphocytic leukemia. It is classified as a kinase inhibitor.
Show more definitions
- A particular drug for the treatment of chronic lymphocytic leukemia.
How to use "idelalisib" in a sentence
Basic
Advanced
idelalisib
Idelalisib can be administered without regard to food.
Zydelig contains the active substance idelalisib.
Idelalisib was taken until disease progression or unacceptable toxicity.
Effect of other medicinal products on idelalisib pharmacokinetics.
Effect of idelalisib on the pharmacokinetics of other medicinal products.
No human data on the effect of idelalisib on fertility are available.
Idelalisib is not considered to have broad immunosuppressive activity.
Carcinogenicity studies with idelalisib have not been conducted.
Idelalisib in combination with ofatumumab.
Expected effect of idelalisib on drug levels.
Idelalisib in combination with rituximab.
Concurrent administration of salmeterol and idelalisib is not recommended.
Idelalisib induced inflammatory changes in both rats and dogs.
The active substance is idelalisib.
It is not known whether idelalisib and its metabolites are excreted in human milk.
See also
Cases of pneumonitis have been reported in clinical studies with idelalisib.
Idelalisib has been previously approved for the treatment of chronic lymphocytic leukemia.
Zydelig is a cancer medicine containing the active substance idelalisib.
Idelalisib has not been studied in patients with chronic active hepatitis including viral hepatitis.
Any medicine containing idelalisib.
Idelalisib should not be co-administered with alfuzosin.
No patients with severe hepatic impairment were included in clinical studies of idelalisib.
Idelalisib should not be co-administered with sildenafil.
Zydelig is a cancer medicine that contains the active substance idelalisib.
Idelalisib should not be co-administered with cisapride.
There have been cases of PJP after stopping idelalisib treatment.
Idelalisib should not be co-administered with amiodarone or quinidine.
Serum concentrations Concurrent administration of salmeterol and idelalisib is not recommended.
Idelalisib should not be co-administered with ergotamine or dihydroergotamine.
The current recommendation relates only to provisional measures recommended by the PRAC for idelalisib.
Idelalisib should not be co-administered with lovastatin or simvastatin.
Clinical recommendation upon co-administration with idelalisib.
Idelalisib should not be co-administered with quetiapine or pimozide.
Based on findings in animals, idelalisib may cause foetal harm.
Idelalisib treatment should be discontinued in patients with evidence of infection or viraemia ;.
However, the lymphocyte counts take longer to decrease to normal levels with idelalisib.
If pneumonitis is suspected, idelalisib should be interrupted and the patient treated accordingly.
Caution should be exercised, including consideration of dose reduction, when co-administering tadalafil with idelalisib.
Idelalisib should not be co-administered with colchicine to patients with renal or hepatic impairment.
Cases of pneumonitis and organising pneumonia ( some with fatal outcome ) have been reported with idelalisib.
Serum concentrations Idelalisib should not be co-administered with alfuzosin.
Immune-related skin reaction or other immune-related adverse reactions in patients with prior treatment with idelalisib.
Serum concentrations Idelalisib should not be co-administered with quetiapine or pimozide.
Table 2, Adverse drug reactions reported in clinical studies in subjects with haematologic malignancies receiving idelalisib.
Idelalisib is a competitive inhibitor of the ATP binding site of the PI3Kδ catalytic domain.
Ergotamine, dihydroergotamine ↑ serum concentrations Idelalisib should not be co-administered with ergotamine or dihydroergotamine.
Table 7, Summary of response in subjects with FL treated with idelalisib IRC assessment.
The pharmacokinetics of idelalisib in paediatric subjects have not been established see section 4.2.
We found that the patient's cells were exceptionally sensitive to the phosphoinositide 3-kinase inhibitor idelalisib.
Idelalisib induced lymphoid depletion in spleen, thymus, lymph nodes and gut-associated lymphoid tissue.
